SAR 120.8
(0.0%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | 3.52 Billion SAR | 0.04% |
2022 | 3.52 Billion SAR | 6.54% |
2021 | 3.3 Billion SAR | 14.75% |
2020 | 2.87 Billion SAR | 46.3% |
2019 | 1.96 Billion SAR | 1.95% |
2018 | 1.93 Billion SAR | -3.82% |
2017 | 2 Billion SAR | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q1 | 854.65 Million SAR | -1.2% |
2024 Q3 | 851 Million SAR | -9.35% |
2024 Q2 | 938.7 Million SAR | 9.83% |
2023 Q4 | 865.06 Million SAR | -1.04% |
2023 FY | 3.52 Billion SAR | 0.04% |
2023 Q3 | 874.17 Million SAR | -2.45% |
2023 Q2 | 896.08 Million SAR | 1.03% |
2023 Q1 | 886.92 Million SAR | 6.63% |
2022 Q2 | 926.3 Million SAR | 8.76% |
2022 Q1 | 851.72 Million SAR | 5.52% |
2022 Q3 | 911.05 Million SAR | -1.65% |
2022 FY | 3.52 Billion SAR | 6.54% |
2022 Q4 | 831.8 Million SAR | -8.7% |
2021 FY | 3.3 Billion SAR | 14.75% |
2021 Q4 | 807.2 Million SAR | -5.9% |
2021 Q3 | 857.79 Million SAR | -0.25% |
2021 Q2 | 859.96 Million SAR | 10.29% |
2021 Q1 | 779.71 Million SAR | 9.82% |
2020 Q1 | 853.08 Million SAR | 0.0% |
2020 FY | 2.87 Billion SAR | 46.3% |
2020 Q4 | 709.96 Million SAR | -8.77% |
2020 Q3 | 778.22 Million SAR | -17.82% |
2020 Q2 | 946.97 Million SAR | 11.01% |
2019 FY | 1.96 Billion SAR | 1.95% |
2018 FY | 1.93 Billion SAR | -3.82% |
2017 FY | 2 Billion SAR | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
Middle East Pharmaceutical Industries Co. | 207.04 Million SAR | -1601.178% |
Al-Dawaa Medical Services Company | 2.06 Billion SAR | -70.593% |
Al-Razi Medical Co. | 14.07 Million SAR | -24926.629% |
Almujtama Alraida Medical Co. | 129.2 Million SAR | -2626.037% |